Cargando…
A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614158/ https://www.ncbi.nlm.nih.gov/pubmed/36313642 http://dx.doi.org/10.3389/fonc.2022.1000823 |
_version_ | 1784820132311203840 |
---|---|
author | Yu, Yingdian Xue, Wenyuan Liu, Zefeng Chen, Shang Wang, Jun Peng, Quanzhou Xu, Linhao Liu, Xin Cui, Chunhui Fan, Jian-Bing |
author_facet | Yu, Yingdian Xue, Wenyuan Liu, Zefeng Chen, Shang Wang, Jun Peng, Quanzhou Xu, Linhao Liu, Xin Cui, Chunhui Fan, Jian-Bing |
author_sort | Yu, Yingdian |
collection | PubMed |
description | Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing was performed in a cohort (n=30) using fresh CRC tissue to discover differentially methylated markers. These markers were subsequently validated with fluorescence quantitative PCR in a cohort (n=221), and the optimal marker was compared to conventional diagnostic methods. Meanwhile, immunohistochemistry was used to verify the effectiveness of the antibody corresponding to this marker in a cohort (n=56). LBX2 achieved an AUC of 0.87, specificity of 87.3%, sensitivity of 75.7%, and accuracy of 81.9%, which outperformed conventional methods including imaging (CT, PET-CT) with an AUC of 0.52, CA199 with an AUC of 0.58, CEA with an AUC of 0.56. LBX2 was also superior to clinicopathological indicators including the depth of tumor invasion and lymphatic invasion with an AUC of 0.61and 0.63 respectively. Moreover, the AUC of LBX2 antibody was 0.84, which was also better than these conventional methods. In conclusion, A novel methylation marker LBX2 could be used as a simple, cost-effective, and reliable diagnostic method for LNM of CRC. |
format | Online Article Text |
id | pubmed-9614158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96141582022-10-29 A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer Yu, Yingdian Xue, Wenyuan Liu, Zefeng Chen, Shang Wang, Jun Peng, Quanzhou Xu, Linhao Liu, Xin Cui, Chunhui Fan, Jian-Bing Front Oncol Oncology Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing was performed in a cohort (n=30) using fresh CRC tissue to discover differentially methylated markers. These markers were subsequently validated with fluorescence quantitative PCR in a cohort (n=221), and the optimal marker was compared to conventional diagnostic methods. Meanwhile, immunohistochemistry was used to verify the effectiveness of the antibody corresponding to this marker in a cohort (n=56). LBX2 achieved an AUC of 0.87, specificity of 87.3%, sensitivity of 75.7%, and accuracy of 81.9%, which outperformed conventional methods including imaging (CT, PET-CT) with an AUC of 0.52, CA199 with an AUC of 0.58, CEA with an AUC of 0.56. LBX2 was also superior to clinicopathological indicators including the depth of tumor invasion and lymphatic invasion with an AUC of 0.61and 0.63 respectively. Moreover, the AUC of LBX2 antibody was 0.84, which was also better than these conventional methods. In conclusion, A novel methylation marker LBX2 could be used as a simple, cost-effective, and reliable diagnostic method for LNM of CRC. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614158/ /pubmed/36313642 http://dx.doi.org/10.3389/fonc.2022.1000823 Text en Copyright © 2022 Yu, Xue, Liu, Chen, Wang, Peng, Xu, Liu, Cui and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yu, Yingdian Xue, Wenyuan Liu, Zefeng Chen, Shang Wang, Jun Peng, Quanzhou Xu, Linhao Liu, Xin Cui, Chunhui Fan, Jian-Bing A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title | A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title_full | A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title_fullStr | A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title_full_unstemmed | A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title_short | A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer |
title_sort | novel dna methylation marker to identify lymph node metastasis of colorectal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614158/ https://www.ncbi.nlm.nih.gov/pubmed/36313642 http://dx.doi.org/10.3389/fonc.2022.1000823 |
work_keys_str_mv | AT yuyingdian anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT xuewenyuan anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT liuzefeng anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT chenshang anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT wangjun anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT pengquanzhou anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT xulinhao anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT liuxin anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT cuichunhui anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT fanjianbing anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT yuyingdian noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT xuewenyuan noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT liuzefeng noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT chenshang noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT wangjun noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT pengquanzhou noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT xulinhao noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT liuxin noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT cuichunhui noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer AT fanjianbing noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer |